• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. Jan 1995; 71(1): 146–149.
PMCID: PMC2033442

Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.

Abstract

The 'growth fraction' of tumours can now be assessed on paraffin sections of tissues using the monoclonal antibody MIB1 by a microwave antigen retrieval technique. The MIB1 labelling index was studied using a CAS 200 image analyser in 177 tumours from women with primary operable breast carcinoma in whom long-term follow-up data were known. Statistical analysis showed a strong association between the MIB1 labelling index and histological grade (P < 0.001), tumour size (P = 0.002), tumour type (P < 0.001) and also patient survival (P < 0.001). No association with lymph node stage (P = 0.974) or regional recurrence (P = 0.185), the presence or absence of distant metastases (P = 0.418), patient age (P = 0.309), menopausal status (P = 0.181) or oestrogen receptor status (P = 0.401) was found in this group of patients. In multivariate analysis for survival, when histological grade, lymph node stage and tumour size were included as well as the MIB1 labelling index, each was found to be of independent significance. If histological grade was not included, MIB1 replaced it as the most important variable predicting for survival in this group of patients. The results suggest that the tumour growth fraction, as assessed by the MIB1 labelling index, is an important predictor of survival.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (793K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aaltomaa S, Lipponen P, Syrjänen K. Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining. Anticancer Res. 1992 Jul-Aug;12(4):1281–1286. [PubMed]
  • Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Palma P. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol. 1992 Oct;98(4):408–418. [PubMed]
  • Betta PG, Robutti F, Pilato FP, Spinoglio G, Bottero G. Correlation of proliferative activity with pathological features in breast carcinoma. Eur J Gynaecol Oncol. 1989;10(6):433–437. [PubMed]
  • Blamey RW, Bishop HM, Blake JR, Doyle PJ, Elston CW, Haybittle JL, Nicholson RI, Griffiths K. Relationship between primary breast tumor receptor status and patient survival. Cancer. 1980 Dec 15;46(12 Suppl):2765–2769. [PubMed]
  • Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JF, Blamey RW, Nicholson RI. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer. 1989 Jun;59(6):943–947. [PMC free article] [PubMed]
  • Campani D, De Negri F, Fabbri R, Martini L, Giani C, Squartini F, Sarnelli R. Estrogen, progesterone receptors and proliferating activity evaluated by immunocytochemistry in breast cancer. Int J Biol Markers. 1991 Jul-Sep;6(3):144–150. [PubMed]
  • Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992 Dec;168(4):357–363. [PubMed]
  • Dawson AE, Norton JA, Weinberg DS. Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry. Am J Pathol. 1990 May;136(5):1115–1124. [PMC free article] [PubMed]
  • Di Stefano D, Mingazzini PL, Scucchi L, Donnetti M, Marinozzi V. A comparative study of histopathology, hormone receptors, peanut lectin binding, Ki-67 immunostaining, and nucleolar organizer region-associated proteins in human breast cancer. Cancer. 1991 Jan 15;67(2):463–471. [PubMed]
  • Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology. 1992 Jun;20(6):479–489. [PubMed]
  • Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 Nov;19(5):403–410. [PubMed]
  • Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983 Jan 15;31(1):13–20. [PubMed]
  • Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710–1715. [PubMed]
  • van Dierendonck JH, Keijzer R, van de Velde CJ, Cornelisse CJ. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res. 1989 Jun 1;49(11):2999–3006. [PubMed]
  • Isola JJ, Helin HJ, Helle MJ, Kallioniemi OP. Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer. 1990 Mar 1;65(5):1180–1184. [PubMed]
  • Kamel OW, Franklin WA, Ringus JC, Meyer JS. Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol. 1989 Jan;134(1):107–113. [PMC free article] [PubMed]
  • Kennedy JC, el-Badawy N, DeRose PB, Cohen C. Comparison of cell proliferation in breast carcinoma using image analysis (Ki-67) and flow cytometric systems. Anal Quant Cytol Histol. 1992 Aug;14(4):304–311. [PubMed]
  • Lee AK, Wiley B, Loda M, Bosari S, Dugan JM, Hamilton W, Heatley GJ, Cook L, Silverman ML. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma. Mod Pathol. 1992 Jan;5(1):61–67. [PubMed]
  • McCormick D, Chong H, Hobbs C, Datta C, Hall PA. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology. 1993 Apr;22(4):355–360. [PubMed]
  • McCormick D, Yu C, Hobbs C, Hall PA. The relevance of antibody concentration to the immunohistological quantification of cell proliferation-associated antigens. Histopathology. 1993 Jun;22(6):543–547. [PubMed]
  • Nicholson RI, Campbell FC, Blamey RW, Elston CW, George D, Griffiths K. Steroid receptors in early breast cancer: value in prognosis. J Steroid Biochem. 1981 Dec;15:193–199. [PubMed]
  • Nicholson RI, Bouzubar N, Walker KJ, McClelland R, Dixon AR, Robertson JF, Ellis IO, Blamey RW. Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer. 1991;27(7):908–913. [PubMed]
  • Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer. 1993;29A(7):1018–1023. [PubMed]
  • Pinder SE, Ellis IO, Galea M, O'Rouke S, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology. 1994 Jan;24(1):41–47. [PubMed]
  • Sahin AA, Ro J, Ro JY, Blick MB, el-Naggar AK, Ordonez NG, Fritsche HA, Smith TL, Hortobagyi GN, Ayala AG. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer. 1991 Aug 1;68(3):549–557. [PubMed]
  • Sasaki K, Matsumura K, Tsuji T, Shinozaki F, Takahashi M. Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer. 1988 Sep 1;62(5):989–993. [PubMed]
  • Stumpp J, Dietl J, Simon W, Geppert M. Growth fraction in breast carcinoma determined by Ki-67 immunostaining: correlation with pathological and clinical variables. Gynecol Obstet Invest. 1992;33(1):47–50. [PubMed]
  • Veronese SM, Gambacorta M. Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. Am J Clin Pathol. 1991 Jan;95(1):30–34. [PubMed]
  • Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P. Proliferation index as a prognostic marker in breast cancer. Cancer. 1993 Jun 15;71(12):3926–3931. [PubMed]
  • Walker RA, Camplejohn RS. Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. Br J Cancer. 1988 Mar;57(3):281–283. [PMC free article] [PubMed]
  • Wrba F, Chott A, Reiner A, Reiner G, Markis-Ritzinger E, Holzner JH. Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. An immunohistochemical study. Oncology. 1989;46(4):255–259. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...